Last reviewed · How we verify
Tri-weekly cisplatin with RT
Cisplatin works by damaging DNA and preventing cancer cells from dividing and growing.
Cisplatin works by damaging DNA and preventing cancer cells from dividing and growing. Used for Locally advanced head and neck cancer, Locally advanced cervical cancer.
At a glance
| Generic name | Tri-weekly cisplatin with RT |
|---|---|
| Also known as | Cisplatin |
| Sponsor | Korea Cancer Center Hospital |
| Drug class | chemotherapeutic agent |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Cisplatin forms covalent bonds with DNA, leading to cross-linking and strand breaks, which disrupts DNA replication and transcription, ultimately causing cell death. When combined with radiation therapy (RT), the cytotoxic effects of both treatments are synergistic, enhancing tumor cell kill.
Approved indications
- Locally advanced head and neck cancer
- Locally advanced cervical cancer
Common side effects
- Nausea and vomiting
- Neutropenia
- Kidney dysfunction
Key clinical trials
- sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC (PHASE1)
- Study of Vinorelbine and Cisplatin as Induction Therapy With Radiotherapy in Patients With Unresectable NSCLC (PHASE2)
- Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |